Stock Information

Markets
TSX20741.75+197.64
TSXV838.33+8.11
DOW34725.47+564.69
S&P 5004431.85+105.34
NASD13770.57+417.79
ASX6838.30-123.30
Commodities
Gold1792.11-4.93
Silver22.47-0.26
Copper4.33-0.10
Palladium2379.43+15.41
Platinum1014.00-9.37
Oil87.29+0.68
Heating Oil2.73+0.01
Natural Gas4.69+0.41
Currencies
BTCUSD37843.67+510.23
USDCAD1.2768+0.0022
USDEUR0.8970-0.0004
USDGBP0.7465-0.0005
USDAUD1.4293+0.0078
USDJPY115.23-0.12

Johnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference

- Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23 rd Ashley McEvoy Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time) .

This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at www.investor.jnj.com .

Keep reading... Show less

Johnson & Johnson Reports Q4 and Full-Year 2021 Results

- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. "Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers" said Joaquin Duato Chief Executive Officer. "Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond."

OVERALL FINANCIAL RESULTS

Keep reading... Show less

Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States

Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of Pharmacoepidemiology, Department of Medicine at Brigham and Women's Hospital and Harvard Medical School .

"We continue to undertake extensive efforts to study the durability of protection offered by the Johnson & Johnson vaccine amidst the ever-changing COVID-19 pandemic," said Mathai Mammen , M.D., Ph.D., Executive Vice President, Pharmaceuticals, Janssen Research & Development LLC, Johnson & Johnson. "While these are rapidly evolving data, we are seeing vaccine effectiveness against COVID-19-related hospitalization of approximately 80 percent from a single shot of the Johnson & Johnson vaccine, and this level of protection holds steady across the length of time studied thus far – up to six months. The robust and sustained durability of our COVID-19 vaccine reflects its unique underlying immunology. We previously reported that our vaccine induces a strong antibody response as well as an especially strong increase in T-cells that is consistent across variants, including Omicron."

Keep reading... Show less
×